Artizan Biosciences

Artizan Biosciences

Artizan Biosciences is developing therapeutic vaccines that can eliminate disease-causing bacteria in the gut microbiome. Artizan leverages a platform technology called IgAseq that can tag and uncover the “bad-actor” bacteria in various diseases, with an initial focus on IBD/Crohn’s disease. The technology was developed in the labs of Noah Palm and Richard Flavell at Yale University.

<< Portfolio